Simulations Plus, Inc. (SLP)
| Market Cap | 899.32M |
| Revenue (ttm) | 64.67M |
| Net Income (ttm) | 10.52M |
| Shares Out | 19.98M |
| EPS (ttm) | 0.53 |
| PE Ratio | 84.91 |
| Forward PE | 67.51 |
| Dividend | $0.24 (0.53%) |
| Ex-Dividend Date | Apr 26, 2024 |
| Volume | 87,185 |
| Open | 45.24 |
| Previous Close | 45.16 |
| Day's Range | 44.67 - 45.69 |
| 52-Week Range | 32.69 - 52.69 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | 57.67 (+28.16%) |
| Earnings Date | Apr 3, 2024 |
About SLP
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as... [Read more]
Financial Performance
In 2023, SLP's revenue was $59.58 million, an increase of 10.52% compared to the previous year's $53.91 million. Earnings were $9.96 million, a decrease of -20.20%.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for SLP stock is "Strong Buy." The 12-month stock price forecast is $57.67, which is an increase of 28.16% from the latest price.
News
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the US FDA has again renewed licenses to its DILIsym QST software to support informed decision-making in drug approvals.
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported earnings for its second quarter of fiscal year 2024. Total revenue for the quarter increased 16% to $18.3 million.
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will hold a conference call to discuss the Company's 2nd quarter FY24 financial results on Wed, April 3, 2024, at 5pm EDT.
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, will be presenting at KeyBanc Capital Markets Virtual Investor Forum on March 20, 2024, at 4:30 p.m. EDT.
Simulations Plus and the University of Bath Awarded New FDA Grant
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus with university partners was awarded a new FDA grant to expand and validate PBBM/PBPK modeling solutions for topical products.
Simulations Plus Extends Collaboration with Major Toxicology Research Agency
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced an extension to its agreement with the NIEHS Division of Translational Toxicology to support their research efforts.
Simulations Plus Launches Corporate Development Initiative
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the launch of a corporate development initiative to pursue strategic investments in early-stage technology companies.
Simulations Plus to Participate in Upcoming Healthcare Conferences
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will be participating in Oppenheimer's 34th Annual Healthcare Life Sciences Conference and BTIG at Snowbird on February 13-14, 2024.
Simulations Plus Releases GastroPlus® Version 9.9
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the release of GastroPlus version 9.9 with key enhancements from FDA collaborations, client feedback, and current research.
Simulations Plus Embarks on Collaboration with Northeastern University and The TIM Company Through New FDA Grant
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced a new FDA-funded collaboration with Northeastern University and The TIM Company to develop modified-release drug products.
Simulations Plus Reports First Quarter Fiscal 2024 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported financial results for the 1st quarter of fiscal year 2024; details will be discussed in a conference call at 5pm ET.
Simulations Plus Announces Leadership Appointments Supporting Commitment to Clients and Driving Growth
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced several key leadership appointments and promotions today, including the addition of Dan Szot as Chief Revenue Officer.
Simulations Plus Announces First Quarter Fiscal Year 2024 Earnings and Conference Call Date
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report first quarter fiscal 2024 financial results after the market close on...
Simulations Plus Outlines Paths to Win at 2023 Investor Day
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a virtual investor day today, Nov. 14, 2023, starting at 1:00 pm ET, with presentations by the Company's leadership team.
Simulations Plus to Host Investor Day on Tuesday, November 14th
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, and the leadership team will participate in the Company's virtual Investor Day on Tuesday, Nov 14, at 1 p.m. ET.
Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported financial results for the 4th quarter and full fiscal year 2023. Total FY23 revenue increased 11% to $59.6 million.
Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a conference call & webcast on October 25, 2023, at 5pm ET to discuss 4th quarter & fiscal year 2023 financial results.
Simulations Plus Receives New FDA Grant Award
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus was awarded a new funded grant from the U.S. FDA to validate best practices for PBBM/PBPK modeling workflows to simulate VBE studies.
Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus hosted its first University+ PBPK Summer Camp, an intensive 8-week PBPK modeling course for more than 80 attendees from 26 countries.
Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)
LANCASTER, Calif.--(BUSINESS WIRE)--Dr. Viera Lukacova, Chief Science Officer of Simulations Plus, was selected to be a Fellow of the American Association of Pharmaceutical Scientists.
Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment
LANCASTER, Calif.--(BUSINESS WIRE)--The July 2023 issue of Clinical Pharmacology & Therapeutics published research where DILIsym was used to predict liver safety of CBD & VPA treatments.
Simulations Plus Releases ADMET Predictor® 11
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the release of ADMET Predictor 11 with significant enhancements expressly designed to accelerate drug discovery research.
Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported revenue growth in the 3rd quarter of FY23 with 3Q revenue up 9% to $16.2 million; 9mo revenue up 4% to $43.9 million.
Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a conference call and webcast on July 6, 2023, at 5pm EDT to discuss the financial results from the 3rd quarter of FY2023.
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today the acquisition of Immunetrics, Inc., an addition of important and proven QSP technology in new therapeutic areas.